<DOC>
	<DOCNO>NCT00077870</DOCNO>
	<brief_summary>This randomize , placebo-controlled , multicenter , blind Phase I/II , investigator subject-blinded study safety escalate dos ocrelizumab combination MTX subject moderate severe RA</brief_summary>
	<brief_title>A Study Evaluate Safety Escalating Doses Ocrelizumab Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Ability willingness provide write informed consent comply requirement protocol Diagnosis RA least 6 month accord revised 1987 ACR criterion classification RA Positive serum RF Current treatment RA outpatient basis Contact local site list inclusion criterion Bone joint surgery ( include joint fusion ) within 8 week prior screen joint surgery plan within 24 week randomization Rheumatic autoimmune disease RA significant systemic involvement secondary RA ( e.g. , vasculitis , pulmonary fibrosis , Feltyï¿½s syndrome ) Functional Class IV define ACR classification functional status RA History current inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) systemic rheumatic disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , overlap syndrome ) Contact local site list exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Moderate severe rheumatoid arthritis</keyword>
</DOC>